Ovarian Cancer Articles | Page 3

Inheritance Matters: The Race to Prevent New Ovarian Cancer Cases
Emerging data have confirmed that ovarian cancer is a much more heterogeneous disease than previously recognized.
The FDA’s recent approvals of novel anti-PARP agents as maintenance therapy for patients with previously treated advanced ovarian cancer highlight an issue that has received inadequate attention in the peer-reviewed oncology literature.
Mansoor Raza Mirza, MD, discusses the initial findings and next steps for the promising niraparib plus bevacizumab combination in ovarian cancer, as well as overall advances with PARP inhibitors in the field.
HIPEC Improves Survival in Advanced Ovarian Cancer
Adding hyperthermic intraperitoneal chemotherapy to interval cytoreductive surgery improved relapse-free survival and overall survival for women with newly diagnosed stage III epithelial ovarian cancer.
Markman Proposes Shift in Ovarian Cancer Clinical Trial Paradigm
Maurie Markman, MD, discusses the need to change the paradigm of clinical trials and FDA approvals in ovarian cancer. 
Letrozole Maintenance Therapy Improves RFS in Ovarian Cancer
Women with ER-positive advanced high-grade serous ovarian cancer assigned to maintenance therapy with letrozole were more likely to be recurrence-free at 24 months.
Targeting Tumor Vasculature in Ovarian Cancer
Robert L. Coleman, MD, discusses targeting tumor vasculature and angiogenesis in ovarian cancer.
Future of Immunotherapy in Ovarian Cancer to Include Combinations
Bradley J. Monk, MD, discusses pivotal trials, as well as the potential for immunotherapy in ovarian cancer.
FDA Grants Priority Review to Maintenance Rucaparib for Ovarian Cancer
The FDA has granted a priority review to a supplemental new drug application for rucaparib (Rubraca) for use as a maintenance treatment for patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.
Time Between Neoadjuvant and Adjuvant Chemo Impacts OS in Ovarian Cancer
Patients with ovarian cancer who begin postoperative adjuvant chemotherapy within 42 days of ending neoadjuvant chemotherapy have superior survival compared to those who initiate therapy after that point.
Publication Bottom Border
Border Publication